Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02245568 · ClinicalTrials.gov registry record · Phase 3
Open-Label Study of Leuco-methylthioninium Bis(Hydromethanesulfonate) (LMTM) in Subjects With Alzheimer's Disease or Behavioral Variant Frontotemporal Dementia (bvFTD)
A Phase 3 study, sponsored by TauRx Therapeutics.
- Terminated
- Registry status
- Phase 3
- Development phase
- 913
- Enrollment target
NCT02245568: Clinical Trial Phase 3 study, sponsored by TauRx Therapeutics.
NCT02245568 is a Phase 3 study that was terminated before completion, run by TauRx Therapeutics. The registered enrollment target is 913 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02245568, a Phase 3 study, was terminated before completion, sponsored by TauRx Therapeutics.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 913 participants
- Enrollment target
Study Summary
The purpose of this study is to provide subjects who have completed participation in a Phase 2 or Phase 3 trial of LMTM continued access to therapy and to evaluate the long-term safety of LMTM.
Interventions
- DRUG LMTM
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 913 participants |
| Start Date | 2014-08 |
| Est. Completion | 2017-05 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02245568
The ClinicalTrials.gov registry entry for NCT02245568 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 913 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is TauRx Therapeutics, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which LMTM is the first listed.
NCT02245568 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02245568 about?
NCT02245568 is a clinical study titled "Open-Label Study of Leuco-methylthioninium Bis(Hydromethanesulfonate) (LMTM) in Subjects With Alzheimer's Disease or Behavioral Variant Frontotemporal Dementia (bvFTD)". The purpose of this study is to provide subjects who have completed participation in a Phase 2 or Phase 3 trial of LMTM continued access to therapy and to evaluate the long-term safety of LMTM.
What is the current status of trial NCT02245568?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 913 participants. The study started on 2014-08. Estimated completion is 2017-05.
What interventions are being tested in trial NCT02245568?
The interventions under investigation include: LMTM (DRUG).
Who is sponsoring clinical trial NCT02245568?
This trial is sponsored by TauRx Therapeutics, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.